PharmaFrontiers data shows improvements for multiple sclerosis patients

By Elaine Rigoli

Tampa, Fla., April 13 - PharmaFrontiers Corp. announced Thursday that two ongoing phase 1/2 clinical trials have shown reductions in relapse rate and alleviation of multiple sclerosis (MS) symptoms.

A phase 2b clinical trial with the T-cell vaccination, Tovaxin, is planned for the second quarter of 2006, the company said in a news release.

MS, an inflammatory, demyelinating disorder of the human central nervous system is the leading cause of non-traumatic neurological disability in young adults.

The pathogenesis of MS involves antigen-specific T cells directed against the protective myelin sheath of the neural network leading to a blocking of the transmission of nerve impulses.

Over time exacerbations of the disease occur, leading to debilitating symptoms and eventually total disability.

PharmaFrontiers has developed a novel technology that uses an autologous T-cell vaccine known as Tovaxin, composed of Myelin Reactive T cell lines against the major proteins of the myelin sheath, myelin basic protein, proteolipid protein and myelin oligodendrocyte glycoprotein, the release said.

Located in The Woodlands, Texas, PharmaFrontiers' strategy is to develop and commercialize cell therapies to treat several major disease areas such as cardiac and pancreatic conditions, multiple sclerosis and rheumatoid arthritis.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.